Rheumatoid arthritis (RA) is a chronic immune-mediated condition with enormous socioeconomic and individual impact. Despite the availability of various treatment options, every patient seems to respond differently. ​Furthermore, the unsuccessful choice of the most suitable medication for a particular patient can lead to a scenario in which the patient consumes a drug that doesn’t align with their body’s response, ultimately aggravating the patient’s condition. We, at SQUEEZE, in synergy with other EU-wide activities, work to validate clinical, laboratory, molecular, digital, and behavioural biomarkers to help tailor the best treatment to the individual patient.​ Our aim is to improve the efficacy, safety, and satisfaction with existing therapies (by squeezing the most out of them!).​